Patent US7521191B2 successfully refreshed from Google Patents.
US7521191B2
Active / In Force
US
⏱️ 0.4 years remaining
siRNA targeting connexin 43
Assignee: Thermo Fisher Scientific Inc
•
Filing: 2007-03-30
•
Granted: 2009-04-21
•
Expires: 2027-03-30
Abstract
Abstract Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to connexin 43 (gap junction protein alpha 1).
Inventors
- 👤 Anastasia Khvorova
- 👤 Angela Reynolds
- 👤 Devin Leake
- 👤 William Marshall
- 👤 Steven Read
- 👤 Stephen Scaringe
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 12:09
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61P; A61P43/00; C12N15/111; C12N15/1135; G; G16; G16B; G16B20/00; C12N2310/00; C12N2310/10; C12N2310/11; C12N2310/14; C12N2320/00; C12N2320/10; C12N2320/11
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
86 words
An siRNA molecule, wherein said siRNA molecule consists of: (a) a duplex region; and (b) either no overhangs regions or at least one overhang region, wherein each overhang region comprises six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region together form said duplex region and said duplex region is 19-30 base pairs in length and said antisense region comprises a sequence that is the complement of SEQ. ID. NO. 470.
Claim 2
Dependent Claim
86 words
An siRNA molecule, wherein said siRNA molecule consists of: (a) a duplex region; and (b) either no overhangs regions or at least one overhang region, wherein each overhang region comprises six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region together form said duplex region and said duplex region is 19-30 base pairs in length and said antisense region comprises a sequence that is the complement of SEQ. ID. NO. 470.
Claim 3
Dependent Claim
21 words
The siRNA molecule of claim 1 , wherein said antisense region and said sense region are each 19-25 bases in length.
Claim 4
Dependent Claim
21 words
The siRNA molecule of claim 2 , wherein said antisense region and said sense region are each 19 bases in length.
Claim 5
Dependent Claim
17 words
The siRNA molecule of claim 1 , wherein said siRNA molecule has at least one overhang region.
Claim 6
Dependent Claim
15 words
The siRNA molecule of claim 1 , wherein said siRNA molecule has no overhang regions.
Claim 7
Dependent Claim
17 words
The siRNA molecule of claim 2 , wherein said siRNA molecule has at least one overhang region.
Claim 8
Dependent Claim
15 words
The siRNA molecule of claim 2 , wherein said siRNA molecule has no overhang regions.
Claim 9
Dependent Claim
17 words
The siRNA molecule of claim 3 , wherein said siRNA molecule has at least one overhang region.
Claim 10
Dependent Claim
15 words
The siRNA molecule of claim 3 , wherein said siRNA molecule has no overhang regions.
Claim 11
Dependent Claim
49 words
A chemically synthesized siRNA molecule that directs cleavage of mRNA via RNA interference, wherein: a. each strand of said siRNA molecule is between 19 and 30 nucleotides in length; and b. one strand of said siRNA molecule comprises a sequence that is the complement of SEQ. ID. NO. 470.
Claim 12
Dependent Claim
49 words
A chemically synthesized siRNA molecule that directs cleavage of mRNA via RNA interference, wherein: a. each strand of said siRNA molecule is between 19 and 30 nucleotides in length; and b. one strand of said siRNA molecule comprises a sequence that is the complement of SEQ. ID. NO. 470.
Claim 13
Dependent Claim
21 words
The chemically synthesized siRNA molecule of claim 10 , wherein each strand of said siRNA molecule is 19 nucleotides in length.
Claim 14
Dependent Claim
145 words
A pool of at least two siRNAs, wherein said pool comprises a first siRNA and a second siRNA, wherein said first siRNA is the siRNA molecule of claim 1 and the duplex region of said first siRNA is a first duplex region and said second siRNA consists of a second duplex region and either no overhang regions or at least one overhang region, wherein each overhang region comprises six or fewer nucleotides, wherein the second duplex region of said second siRNA comprises a second sense region and a second antisense region, wherein said second sense region and said second antisense region together form said second duplex region and said second duplex region is 19-30 base pairs in length and said second antisense region comprises a sequence that is the complement of a sequence selected from the group consisting of SEQ ID NO. 438-469 and 471-587.
Claim 15
Dependent Claim
19 words
The pool of claim 12 , wherein said first siRNA and said second siRNA each have no overhang regions.
Claim 16
Dependent Claim
23 words
The pool of claim 12 , wherein said first duplex region and said second duplex region are each 19-25 base pairs in length.
Claim 17
Dependent Claim
23 words
The pool of claim 14 , wherein said first duplex region and said second duplex region are each 19 base pairs in length.
Claim 18
Dependent Claim
15 words
The pool of claim 15 , wherein said first duplex region contains no overhang regions.
Claim 19
Dependent Claim
15 words
The pool of claim 15 , wherein the second duplex region contains no overhang regions.
Claim 20
Dependent Claim
17 words
The pool of claim 15 , wherein the first duplex region contains at least one overhang region.
Claim 21
Dependent Claim
17 words
The pool of claim 15 , wherein the second duplex region contains at least one overhang region.
Claim 22
Dependent Claim
19 words
The siRNA molecule of claim 3 , wherein the sense region has the sequence of SEQ ID NO: 470.
References Cited (Backward Citations)
WO2002044321A2
Cited
US20020150945A1
Cited
US20050239731A1
Cited
US20050130181A1
Cited
US20050176025A1
Cited
US20030105051A1
Cited
US20040054155A1
Cited
US20040180357A1
Cited
US20070031844A1
Cited
US20040248299A1
Cited
WO2005001043A2
Cited
US20050186586A1
Cited
US20050181382A1
Cited
WO2006015389A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2012-04-20 | 2012-10-20 | 2013-04-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2016-04-20 | 2016-10-20 | 2017-04-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2020-04-20 | 2020-10-20 | 2021-04-21 | $7700.00 | Window Closed / Lapsed |